SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is facing intense selling pressure as a strengthening dollar and persistent inflation data cool expectations for immediate rate cuts, leading investors to re-evaluate metals as a safe haven. The community is actively debating whether this represents a temporary consolidation or a deeper structural breakdown, with many traders closely watching key support levels amid ongoing global energy and geopolitical volatility.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is generating significant buzz as traders speculate on potential institutional integration and its future role in emerging digital payment systems. The community remains deeply divided, with optimistic bulls eyeing long-term adoption catalysts while skeptics continue to caution against volatility and historical price patterns.

Coeur Mining, Inc. engages in the well-diversified, growing precious metals producer with a focus on generating sustainable, high-quality cash flow and returns from a balanced, prospective asset base in mining-friendly jurisdictions along with commitment to exploration and expansions. It operates through the following segments: Palmarejo, Rochester, Kensington, Wharf and Silvertip. The Palmarejo segment includes a gold-silver complex. The Rochester segment operates an open pit heap leach silver-gold mine in northwestern Nevada. The Kensington segment relates to an underground gold mine located north of Juneau, Alaska. The Wharf segment focuses on an open pit heap leach gold mine located near Lead, South Dakota. The Silvertip segment silver-zinc-lead exploration located in the state of Sonora in northern Mexico. The company was founded in 1928 and is headquartered in Chicago, IL.

Coeur Mining Inc

Coeur Mining is drawing heavy interest from traders as high short interest, record free cash flow, and a pending acquisition of New Gold fuel a potential breakout narrative. Community members remain focused on the stock's significant undervaluation relative to surging gold, silver, and copper prices, with many actively debating the impact of the upcoming merger and looking for strong moves to test year-to-date highs.

UP Fintech Holding Ltd. is an online brokerage firm that focuses on global investors. It provides an online trading platform that enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The firm offers products and services, as well as a user experience to customers through its mobile first strategy. The company was founded by Tian Hua Wu in June 2014 and is headquartered in Singapore.

UP Fintech Holding Ltd - ADR

UP Fintech is trending as investors aggressively position themselves ahead of the company's upcoming earnings release, fueled by strong revenue growth and a record-breaking performance in recent quarters. The community is actively debating the stock's valuation gap compared to sector peers, with many traders discussing potential upside catalysts and the impact of institutional accumulation.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense investor debate as a record-breaking earnings beat and bullish AI-driven guidance are being countered by concerns over increased capital expenditures and profit-taking after a massive year-long rally. While many in the community view the post-earnings pullback as a tactical manipulation by institutions to accumulate shares, others are cautioning that short-term volatility is expected as investors weigh the company's AI infrastructure dominance against macroeconomic uncertainty.

Direxion Shares ETF Trust - Direxion Small Cap Bull 3X ETF

Direxion Daily Small Cap Bull 3X Shares

TNA is trending as traders analyze rotation patterns and volatility within the Russell 2000, with many in the community focusing on short-term scalping and averaging down strategies during price fluctuations. The discourse reflects a mix of sentiment regarding interest rate expectations and the index's sensitivity to macroeconomic shifts, prompting active debates on whether small-cap equities are poised for a significant breakout or continued consolidation.

Almonty Industries, Inc. engages in mining, processing and shipment of tungsten concentrates. Its projects include Los Santos, Valtreixal, Almonty Korea Tungsten, Almonty Korea Moly, and Panasquiera. The company was founded on September 28, 2009 and is headquartered in Toronto, Canada.

Almonty Industries Inc

Almonty Industries is trending as investors bet on the company's critical role in a global 'tungsten supercycle,' driven by Chinese export restrictions and intensified defense-sector demand for non-PRC supply chains. Community discussion is heavily focused on the company's strategic move to secure Western supply independence, with many highlighting long-term potential as its Sangdong mine reaches commercial production.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

MSTX is trending as investors react to a looming 1-for-10 reverse stock split scheduled for mid-March, which has sparked intense debate over the long-term viability of leveraged ETFs and potential volatility decay. While some community members view the current price as a buying opportunity for a bounce, others are warning that such products are primarily meant for short-term trading rather than long-term holds.

abrdn ETF - abrdn Physical Platinum Shares ETF

PPLT is trending as investors weigh structural supply deficits and industrial demand against intense volatility driven by algorithmic trading and margin requirement shifts. The community is actively debating whether the metal is deeply undervalued relative to gold or if recent price spikes represent a unsustainable blow-off top.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust (SLV) is facing heavy selling pressure amid a strengthening U.S. dollar and broad risk-off sentiment, leading the community to intensely debate whether this is a temporary dip or a sign that the safe-haven narrative is currently broken. Traders are actively discussing the influence of institutional market makers and high-volume put hedging, while bulls remain fixated on long-term supply deficits and geopolitical instability as reasons to hold or accumulate physical silver despite the downward trend.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>A Novo executive noted that many customers are unaware that the company already makes oral semaglutide for type 2 diabetes under the name Rybelsus, sparking the branding change.</li><li>Novo also said on Wednesday that it has filed an application with the FDA seeking approval for Ozempic tablets 25 mg in adults with type 2 diabetes.</li></ul>Danish drugmaker Novo Nordisk (NVO) said on Wednesday that the U.S. Food and Drug Administration has approved naming pill versions of some doses of its semaglutide for the treatment of type 2 diabetes as Ozempic pills.Novo has been selling oral semaglutide for diabetes since 2019. However, it was previously called Rybelsus and was available at 3 mg, 7 mg, and 14 mg doses. Ozempic pills will be available in doses 1.5 mg, 4 mg, and 9 mg.<h2 class="st-heading-2">Why The Name Change?</h2>“By bringing the oral and injectable options under the Ozempic name, we’re helping make it clear that both contain semaglutide from Novo Nordisk and are approved to treat type 2 diabetes. The medicine and how it works remain the same; this simply makes the choices clearer to understand. There’s only One Ozempic…now in two presentations.” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916488">said</a> Ed Cinca, Senior Vice President of Marketing &amp; Patient Solutions at Novo Nordisk.Cinca also noted that many customers are unaware that the company already makes oral semaglutide for type 2 diabetes under the name Rybelsus, sparking the branding change.<h2 class="st-heading-2">Launch Timeline</h2>The Ozempic pill will be launched in Q2 2026. The new formulation offers the same efficacy and safety profile as the originally approved formulation, the company said, while adding that the new doses were approved based on a bioequivalence study and the clinical trial program for Rybelsus tablets.Novo got the approval of the U.S. Food and Drug Administration (FDA) for the Wegovy pill in December last year and launched it in early January. The weight-loss drug has had a great kickstart so far.Novo also said on Wednesday that it has filed an application with the FDA seeking approval for Ozempic tablets 25 mg in adults with type 2 diabetes. The company now expects the agency to provide a decision on the application by 2026-end.<h2 class="st-heading-2">Flat Growth In Diabetes Segment</h2>Novo on Tuesday said that sales from its diabetes segment remained more-or-less flat on a reported basis in 2025 at DKK 207.11 billion while sales from its obesity segment increased 26% in Danish kroner to DKK 82.35 billion.The company now expects adjusted sales to fall between 5% and 13%, and operating profit could decline by up to 13%. The company flagged concerns for the year including fierce competition, lower realized prices, and expiry of patent on the active ingredient in its best-selling Wegovy and Ozempic drugs in a few markets outside the U.S.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO stock stayed within the ‘bullish’ territory while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> has fallen 43% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rklb-asts-stocks-dip-amid-selloff-after-spacex-xai-merger-spurred-rally/cZbj9ElR4NO">RKLB, ASTS Stocks Dip Amid Selloff After SpaceX-xAI Merger Spurred Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk To Launch Ozempic Pills Following Flat Growth In Diabetes Segment In 2025

The Ozempic pill will be launched in Q2 2026 and be available in doses 1.5 mg, 4 mg, and 9 mg.

Equity

The Ozempic pill will be launched in Q2 2026 and be available in doses 1.5 mg, 4 mg, and 9 mg.


<ul class="summary-bullets"><li>The company flagged concerns for the year including fierce competition, lower realized prices, and expiry of patent on the active ingredient in its best-selling Wegovy and Ozempic drugs in a few markets outside the U.S.&nbsp;</li><li>The updated guidance comes on the heels of the company reporting full-year 2025 net sales of DKK309.06 billion, below an analyst estimate of DKK346.97 billion.</li><li>Novo’s sales from its diabetes segment remained more-or-less flat on a reported basis in 2025 at DKK207.11 billion while sales from its obesity segment increased 26% in Danish kroner to DKK82.35 billion.</li></ul>Shares of Danish drugmaker Novo Nordisk (NVO) plummeted 14% on Tuesday after the company said that it sees fiscal 2026 adjusted sales down 5% to 13% as it gears up to face pricing headwinds and a competitive market.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ml-eu.globenewswire.com/Resource/Download/7c7c1d6f-42c0-4e8f-821c-93ff9a0858c0">flagged </a>concerns for the year including fierce competition, lower realized prices, and expiry of patent on the active ingredient in its best-selling Wegovy and Ozempic drugs in a few markets outside the U.S.Novo also sees adjusted operating profit fall as much as 13% in fiscal 2026 at constant exchange rates.<h2 class="st-heading-2">2025 Earnings</h2>The updated guidance comes on the heels of the company reporting full-year 2025 net sales of DKK309.06 billion ($48.94 billion), up 6% year-over-year on a reported basis, but below an analyst estimate of DKK346.97 billion.Diluted earnings per share for the year came in at DKK23.03, up from DKK22.63 in 2024, and below a Wall Street estimate of DKK23.4.Operating profit, meanwhile, decreased by 1% in Danish kroner to DKK127.66billion.<h2 class="st-heading-2">Executive Take</h2>CEO Mike Doustdar said that 2025 was a "challenging year” for the company.“However, we are very encouraged by the promising early uptake from the US launch of Wegovy pill, and we remain confident in our ability to drive volume growth over the coming years,” Doustdar said.“Also for this year, we look forward to regulatory decisions for next-generation treatments, such as Mim8 within haemophilia and CagriSema within obesity, as well as a number of exciting R&amp;D read-outs, including phase 3 read-outs for etavopivat and ziltivekimab," he added.Novo got the approval of the U.S. Food and Drug Administration (FDA) for the Wegovy pill in December last year and launched it in early January. The drug has had a great kickstart so far.In contrast, rival Eli Lilly and Co. (LLY) is still awaiting FDA approval on its oral weight-loss drug, giving Novo a few months of solid head start to cement its position in the market. However, Lilly is currently overtaking Novo in injectable weight loss drugs. &nbsp;<h2 class="st-heading-2">Blockbuster Drug Sales</h2>Novo said on Tuesday that sales from its diabetes segment remained more-or-less flat on a reported basis in 2025 at DKK 207.11 billion while sales from its obesity segment increased 26% in Danish kroner to DKK 82.35 billion.Sales of the company’s blockbuster diabetes drug Ozempic came in at DKK130.11 billion for the year, while Wegovy sales came in at DKK79.11 billion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> has dropped about 39% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-continues-to-rejig-lineup-in-run-up-to-vehicle-autonomy/cZb0GTWR4mS">Tesla Continues To Rejig Lineup In Run Up To Vehicle Autonomy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Exchange Rate: DKK1= $0.16

Novo Nordisk Shares Tumble On 2025 Earnings Miss, Weak Sales Forecast And Competition Concerns

The drugmaker now expects fiscal 2026 adjusted sales down 5% to 13%.

<ul class="summary-bullets"><li>Novo and Aspect have been collaborating since 2023 to develop cellular medicines.</li><li>Under the deal, Aspect has acquired rights to stem cell-derived islet cell and hypoimmune cell engineering technologies from Novo Nordisk and will now lead their development.&nbsp;</li><li>Novo, in turn, will make an additional equity investment in Aspect and provide research funding.</li></ul>Danish drugmaker Novo Nordisk (NVO) said on Tuesday that it is looking to develop new medicines for diabetes as part of its new partnership with Canadian biotech firm Aspect Biosystems.Novo and Aspect have been collaborating since 2023 to develop cellular medicines. The companies <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916478">said</a> that the new partnership phase builds on the momentum achieved in the existing collaboration.<h2 class="st-heading-2">Deal Terms</h2>Under the deal, Aspect has acquired rights to stem cell-derived islet cell and hypoimmune cell engineering technologies from Novo Nordisk. This refers to technology allowing for making insulin-producing cells from stem cells for diabetes treatment and modifying cells to evade the immune system, thereby avoiding immune rejection. The privately-held company will now lead its development, manufacturing and commercialisation.Novo, in turn, will make an additional equity investment in Aspect and provide research funding. It will also retain rights to expand its role in late-stage development and commercialisation as well. &nbsp;Novo Nordisk will be eligible to receive royalties and milestone payments on future product sales from Aspect. However, the companies didn’t provide the financial terms of the agreement.<h2 class="st-heading-2">Novo On Lookout For More</h2>Last week, Novo said it is on the lookout for merger and acquisition deals to boost its drug portfolio.Novo’s CEO Mike Doustdar said during the annual JP Morgan Healthcare conference that the company will continue searching for molecules, assets, and companies that are complementary to its portfolio. Doustdar said that the company can afford any amount for an asset, provided it is worth it.Novo’s best-selling drugs now include Wegovy and Ozempic for weight loss and diabetes, respectively.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO shares</a> have fallen 25% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lululemon-stock-slips-after-reportedly-removing-see-through-leggings-from-website/cmUuHw8R4OO">Lululemon Stock Slips 6% After Reportedly Removing “See-Through” Leggings From Website</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Nordisk Inks Deal With Canada’s Aspect Biosystems To Find More Diabetes Meds Besides Ozempic

Novo and Aspect have been collaborating since 2023 to develop cellular medicines, and said that the new partnership phase builds on the momentum achieved in the existing collaboration.

<ul class="summary-bullets"><li>Ryanair in its post on X described Musk’ latest comments as ‘Twitshit’.</li><li>The feud between the two leaders erupted last week after O’Leary said he wouldn’t consider installing SpaceX’s Starlink internet for the budget airline’s fleet.&nbsp;</li><li>This week, Musk posted a poll asking users whether he should buy Ryanair and "restore a Ryan as their rightful ruler.”</li></ul>Ryanair has continued the online brawl between Elon Musk and its CEO Michael O’Leary as the airline in a post on X said that its CEO O’Leary will address the recent comments made by the world’s richest man Musk in a press conference on Wednesday.The airline’s official X account <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/Ryanair/status/2013651269596955135">said</a> that Ryanair CEO, Michael O’Leary will “address/undress Elon Musk’s Twitter tantrum” at a press conference on Jan. 21, describing Musk’ latest comments as ‘Twitshit’.“Musk knows even less about airline ownership rules than he does about aircraft aerodynamics,” said Michael O’Leary in the post.&nbsp;The airline also said that it is launching a “Great Idiots seat sale especially for Elon and any other idiots on X.”&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/RYANAIR_2_PNG_c7848ff5ec.webp" alt="The airline said that it is launching a “Great Idiots seat sale especially for Elon and any other idiots on X.”" width="591" height="612"></figure>Ryanair joined the online sparring last week. In response to a post asking what piece of propaganda it would never fall for, the airline replied bluntly, "Wi-Fi on planes."&nbsp;<h2 class="st-heading-2">Weeks Long Feud&nbsp;</h2>The feud between the two leaders erupted last week after O’Leary said he wouldn’t consider installing SpaceX’s Starlink internet for the budget airline’s fleet because of fuel costs from the weight and drag of the antenna mounted on the roof of the cabin. Musk called O’Leary ‘misinformed’ who in return called him an ‘idiot’."I would pay no attention whatsoever to Elon Musk — he's an idiot," O'Leary said, adding that while Musk is "very wealthy," he is "still an idiot."&nbsp;Musk fired back on X late last week, calling O'Leary "an utter idiot" and suggesting he be fired. That exchange prompted users to suggest that Musk simply buy the airline himself and implement the changes.This week, Musk posted a poll on X asking users whether he should buy Ryanair and "restore a Ryan as their rightful ruler." Nearly 78% of respondents voted in favor, while the rest voted against.<h2 class="st-heading-2">O’Leary Reign At Ryanair</h2>O'Leary has built the airline into the biggest budget carrier in the region over several decades at the job. He is also among the top 10 shareholders in the airline.&nbsp;Recently he was awarded a major bonus package for achieving certain performance metrics on the stock. The U.S.-listed stock of Ryanair has risen 62% over the past year.&nbsp;<h2 class="st-heading-2">Musk’s Previous Polls</h2>Musk has polled his followers in the past on various matters ranging from whether Tesla should accept Dogecoin as payment for its electric vehicles to if he should sell some stake in the carmaker.&nbsp;In 2022, he polled users on whether they wanted an edit button to edit their tweets on then called Twitter now X, shortly after revealing stake in the social media platform.&nbsp;After acquiring the platform, Musk polled whether he should step down as the head of the company. Musk later hired Linda Yaccarino to replace him as CEO in May 2023.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around RYAAY trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Retail sentiment around SPACEX trended in ‘bearish’ territory amid ‘high’ message volume.&nbsp; &nbsp;

Ryanair Boeing 737 MAX 8 as seen during taxiing, take off and flying phase in Eindhoven Airport.

Ryanair Turns Up Heat After Calling Press Briefing On Musk, Launches ‘Great Idiots Seat Sale’ Taking Aim At SpaceX Owner 

The airline’s official X account said that Ryanair CEO, Michael O’Leary will “address/undress Elon Musk’s Twitter tantrum” at a press conference on Jan. 21.

<ul class="summary-bullets"><li>If approved, Ianalumab could become the first targeted treatment for Sjögren’s disease.&nbsp;</li><li>The Breakthrough Therapy designation was granted to Novartis on the basis of clinical evidence supporting the drug’s potential.</li><li>In Novartis’ late-stage trials evaluating the efficacy and safety of Ianalumab in patients with Sjögren’s disease, the drug delivered a clinically meaningful benefit.</li></ul>Shares of Novartis (NVS) rose 1% on Friday after the U.S. Food and Drug Administration granted its drug Ianalumab a breakthrough therapy designation in the treatment of Sjögren’s disease.Sjögren’s disease is a systemic, chronic autoimmune disorder that causes inflammation and tissue damage, impacting the entire body. It primarily affects exocrine glands, leading to excessive dryness, with over 90% of patients experiencing dry eyes and dry mouth.According to Novartis, 50% of people with Sjögren’s are undiagnosed, though it is the second-most prevalent rheumatic autoimmune disease.Novartis looks to submit data from its many trials of Ianalumab with health authorities starting in early 2026 for potential approval. If approved, it could become the first targeted treatment for Sjögren’s disease, as per Novartis.<h2 class="st-heading-2">The Designation</h2>The Breakthrough Therapy designation, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-ianalumab-receives-fda-breakthrough-therapy-designation-sjogrens-disease">granted</a> to Novartis on the basis of clinical evidence supporting the drug’s potential, is intended to expedite the review of medicines that treat a serious or life-threatening condition. Ianalumab was previously awarded the FDA’s Fast Track designation in 2016.In Novartis’ late-stage trials that evaluated the efficacy and safety of Ianalumab in patients with Sjögren’s disease, the drug delivered a clinically meaningful benefit, showing improvement in disease activity and reductions in patient burden. Further, the drug demonstrated a favorable safety profile with an overall incidence of adverse events comparable to placebo.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVS stock stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<a href="https://stocktwits.com/symbol/NVS">NVS stock</a> has gained nearly 48% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvo-shares-rise-on-strong-kickstart-for-wegoy-pill-in-us/cmUlCCgR4Bq">NVO Shares Rise On Strong Kickstart For Wegovy Pill In US: Retail Eyes Up To $110 As ‘Fair Value’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

NVS Stock Rises After FDA Grants Breakthrough Therapy Designation For Autoimmune Disorder Treatment

Novartis looks to submit data from its many trials of Ianalumab with health authorities starting in early 2026 for potential approval.

<ul class="summary-bullets"><li>The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company said.&nbsp;</li><li>It will also result in the shut down of sites in the Netherlands, Switzerland, U.S. and China.</li><li>Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.</li></ul> Galapagos NV (GLPG) on Monday announced that its Board of Directors has decided to initiate the wind-down of the company’s cell therapy activities, sending shares up 6% in Monday’s after hours trading.The company had announced its intent to wind down the activities after a strategic review and sale process in October but had held on acting on it until it completed communicating with work councils in the Belgium and Netherlands. The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/05/3213177/0/en/Galapagos-Announces-Board-Decision-to-Initiate-Wind-Down-of-Cell-Therapy-Activities.html">said</a>.It will also result in the shut down of sites in the Netherlands, Switzerland, the U.S. and China. The U.S. facilities to be shut down include one in Princeton and another in Pittsburgh, the company said. More details about the wind down, including details pertaining to its timeline and costs, will be provided with the company’s full year earnings in February, it added.Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.<h2 class="st-heading-2">Future After Wind Down</h2>On Monday, Galapagos said that the wind-down of the cell therapy activities will position it for longer-term growth. The company will continue to manage its non-cell therapy programs and evaluate all strategic alternatives for GLPG3667, an investigational, oral, selective inhibitor of tyrosine kinase 2, to accelerate its development in dermatomyositis and potentially other severe auto-immune indications, the company said.The company will also consider resuming the partnering process for the drug, it said. Galapagos also added that it will continue to maintain its presence at its headquarters in Belgium as well as its hubs in Chicago and San Francisco.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment about GLPG stayed in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<a href="https://stocktwits.com/symbol/GLPG">GLPG stock</a> has gained 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/toyota-us-sales-rise-8-percent-in-q4/cmxMCZPR4Ri">US Heeds Trump To Buy A Toyota: Japanese Automaker’s US Sales Rise 8% In Q4</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A logo of Galapagos, a European pharmaceutical research company, is pictured outside its facility on June 9, 2020 in Leiden, Netherlands. (Photo by Yuriko Nakao/Getty Images) 

Galapagos Stock Rises After Hours On Starting To Wind Down Cell Therapy Activities, Subsequent Workforce Reduction 

The company had announced its intent to wind down the activities after a strategic review and sale process in October.

<ul class="summary-bullets"><li>Brady said that the Prime members have received over €6 million in fare discounts, so “this trial has cost more money than it generates.”</li><li>All existing Prime members will continue to enjoy exclusive monthly low-fare offers until October 2026, but no new members will be allowed to sign up after Friday.</li><li>According to Ryanair’s website, the Prime members get free reserved seats, free travel insurance and access to 12 member-only seat sales and one each month.</li></ul>Ryanair (RYAAY) announced on Friday that it will close its prime member offering from November, following an eight-month trial period during which the European airline noted that the membership cost more than it generated.Chief Marketing Officer Dara Brady said that to date, Ryanair has signed up over 55,000 Prime members, generating over €4.4 million ($5.1 million) in subscription fees. However, Prime members have received over €6 million in fare discounts, so “this trial has cost more money than it generates,” Brady said,The company said that all existing Prime members will continue to enjoy exclusive monthly low-fare offers until October 2026, but no new members will be allowed to sign up after Friday.<h2 class="st-heading-2">Ryanair Prime Membership Details</h2>According to Ryanair’s website, Prime members get free reserved seats, free travel insurance, and access to 12 member-only seat sales, one each month. Prime members get the offer for £79 per annum.Ryanair noted that, based on a passenger who flew 12 times last year, the potential savings so far from the membership were £640 per year. The company added that for a passenger who flew three times last year, the potential savings so far were £415.<h2 class="st-heading-2">Brady’s View</h2>Brady noted that existing Prime members will be allowed to use their seat savings for the remainder of their 12-month membership.“This level of memberships, or subscription revenue does not justify the time and effort it takes to launch monthly exclusive Prime seat sales for our 55,000 Prime members,” Brady said.&nbsp;&nbsp;He noted that the airline has had over 207 million passengers this year and said that they would be trying to offer the lowest fares in Europe to&nbsp;all its customers, and not the subset of 55,000 Prime members.Retail sentiment on <a href="https://stocktwits.com/symbol/RYAAY">Ryanair</a> remained unchanged in the ‘bearish’ territory, with message volumes at ‘normal’ levels, according to data from Stocktwits.U.S.-listed shares of the company have gained nearly 57% this year.€1 = $1.16For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/abercrombie-fitch-catches-retail-attention-after-barclays-raises-price-target-on-hollister-momentum/cL5abTzRELe">Abercrombie &amp; Fitch Catches Retail Attention After Barclays Raises Price Target On Hollister Momentum</a>

Ryanair Pulls Plug On Prime Membership Offering After Trial Proves Too Costly 

Chief Marketing Officer Dara Brady said that to date, Ryanair has signed up over 55,000 prime members, generating over €4.4 million in subscription fees.

<ul class="summary-bullets"><li>Both subcutaneous and oral Amycretin appeared to have a safe and well-tolerated profile in the study, Novo said.</li><li>Novo is now planning to initiate a late-stage trial of Amycretin in patients with type 2 diabetes in 2026.&nbsp;</li><li>The positive announcement comes on the heels of the company's discontinuation of late-stage trials of its GLP-1 drug, Semaglutide, in Alzheimer’s disease.</li></ul> Novo Nordisk (NVO) on Tuesday said that a mid-stage trial evaluating Amycretin in people with type 2 diabetes yielded positive outcomes in both weight loss and reduction in average blood sugar levels.NVO shares traded 3% higher in the pre-market session at the time of writing.<h2 class="st-heading-2">Study Outcomes</h2>Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeks, as compared to 2.6% in patients treated with placebo, and demonstrated statistically significant reductions in average blood sugar levels, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/25/3194155/0/en/Novo-Nordisk-phase-2-trial-with-amycretin-reports-significant-weight-loss-and-HbA1c-reduction-in-type-2-diabetes.html">said</a>.The trial investigated the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous Amycretin and once-daily oral amycretin compared with placebo in 448 people with type 2 diabetes inadequately controlled on metformin. About 40% of the study participants also used a class of drugs known as SGLT2 inhibitors to manage their diabetes before joining the study.Amycretin belongs to the class of drugs known as GLP-1s, used to treat diabetes and obesity, similar to Novo’s blockbuster drugs Wegovy and Ozempic. Both subcutaneous and oral Amycretin appeared to have a safe and well-tolerated profile in the study, Novo said. The common side effects were gastrointestinal, and the vast majority were mild to moderate in severity, the company added.<h2 class="st-heading-2">Plans Ahead</h2>Novo is now planning to initiate a late-stage trial of Amycretin in patients with type 2 diabetes in 2026.Chief Scientific Officer Martin Holst Lange noted that this is the first time Amycretin has been evaluated in this population and added that the company is planning to test the GLP-1 compound across multiple indications starting next year.The positive announcement comes on the heels of the company's discontinuation of late-stage trials of its GLP-1 drug, Semaglutide, in Alzheimer’s disease.The company said on Monday that its late-stage trials evaluating oral Semaglutide in Alzheimer’s disease did not confirm its superiority over placebo in slowing disease progression, and it is subsequently discontinuing them.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down by 48% this year and by about 57% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/autl-stock-soars-pre-market-on-position-recommendation-for-cell-therapy-targeting-cancer-in-uk/cL52LfPREXA">AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study

The trial was investigating the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous amycretin and once-daily oral amycretin compared to placebo in 448 people with type 2 diabetes. 

<ul class="summary-bullets"><li>Semaglutide is the active ingredient in Novo’s blockbuster drugs Wegovy and Ozempic.&nbsp;</li><li>The company said it decided to test the drug in Alzheimer’s disease based on real-world evidence and preclinical models.</li><li>The company conducted two late-stage studies in Alzheimer’s disease, and while an improvement of disease-related biomarkers was observed in both trials with Semaglutide, it did not delay the progression of the disease.</li></ul>Novo Nordisk (NVO) on Monday said that its late-stage trials evaluating oral Semaglutide in Alzheimer’s disease did not confirm its superiority over placebo in slowing disease progression.Shares of the company slumped 11% in the pre-market session at the time of writingSemaglutide is the active ingredient in Novo’s blockbuster weight-loss drug Wegovy. The company said that it decided to test the drug in Alzheimer’s based on real-world evidence studies, pre-clinical models, as well as post-hoc analyses from diabetes and obesity trials. The compound, belonging to the category known as GLP-1 drugs, is marketed as Ozempic and Rybelsus for the treatment of type 2 diabetes as well.<h2 class="st-heading-2">Trial Outcomes</h2>The company conducted two late-stage studies in Alzheimer’s disease, and while an improvement of disease-related biomarkers was observed in both trials with Semaglutide, it did not delay the progression of the disease, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193328/0/en/Novo-Nordisk-A-S-Evoke-phase-3-trials-did-not-demonstrate-a-statistically-significant-reduction-in-Alzheimer-s-disease-progression.html">said</a>. The two trials enrolled a total of 3,808 adults and were aimed at evaluating the efficacy and safety of oral Semaglutide compared to placebo on top of standard of care in early-stage symptomatic Alzheimer’s disease.Alzheimer’s is a leading cause of memory loss or dementia. It is a progressive disease where symptoms gradually worsen over time. Semaglutide appears to have a safe and well-tolerated profile in the studies with patients aged 55-85 suffering from mild cognitive impairment or mild dementia due to Alzheimer’s disease, Novo noted.The company said that it is discontinuing the trials. However, the data generated will continue to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities, it added. The data from the trials will also be presented at future conferences, the company said.<h2 class="st-heading-2">Semaglutide And Its Many Indications</h2>Semaglutide is Novo's biggest asset. In the nine months through the end of September, the company reported sales of DKK 95.264 billion ($14.721.52 billion) from Ozempic, DKK 16.790 billion from Rybelsus and DKK 57.242 billion from Wegovy, togetherly accounting for about 74% of the company’s overall sales in the period.&nbsp;An approval in Alzheimer’s could have helped the company ramp revenue from the compound as its rivalry with American GLP-1 drugmaker Eli Lilly intensifies.&nbsp;The company’s drop in share price prompted a change in CEO earlier this year and layoffs.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 45% this year and by 54% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/btc-holds-86000-crypto-market-back-above-3-trillion-xrp-doge-gain/cL5bex0REQP">Bitcoin Holds $86,000 With Crypto Market Back Above $3 Trillion – XRP, Doge Gain Ahead Of Grayscale’s New ETF Launches</a>For updates and corrections, email newsroom[at]stocktwits[dot]comExchange Rate: DKK1= $0.15

Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies

The company said that it is discontinuing the trials.

BioNTech SE (BNTX) announced on Friday that a late-stage trial, conducted by its partner Duality Biologics in China, has met its primary endpoint of progression-free survival at a pre-specified interim analysis. The trial is evaluating Trastuzumab Pamirtecan versus Trastuzumab Emtansine in patients with certain types of breast cancer.Shares of the company traded 10% higher in the pre-market session on Friday. The <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biontech.de/news-releases/news-release-details/biontech-and-dualitybio-announce-phase-3-trial-adc-candidate">trial</a> enrolled 228 patients with HER2-positive unresectable or metastatic breast cancer, an aggressive form of the disease that has spread and cannot be surgically removed, who previously received Trastuzumab and a taxane-based chemotherapy.On Stocktwits, retail sentiment around BNTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_8_57_36_AM_png_5a9988a80e.webp" alt="BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure> DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.DualityBio Global Medical Officer Hua Mu noted that breast cancer has a high incidence rate in China, with over 350,000 new cases annually.“Together with our partner BioNTech, we plan the development of Trastuzumab Pamirtecan in further tumor types towards BLA application in other regions including the United States and the European Union to maximize its potential for patients around the world,” Mu said.BioNTech also noted that this is the first positive late-stage data readout achieved in the collaboration between the two companies initiated in April 2023. The collaboration aims to accelerate the development of differentiated antibody drug-conjugate therapeutics for solid tumors.BioNTech holds global commercial rights for Trastuzumab Pamirtecan, while DualityBio has commercial rights for Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region.BNTX stock is down by 9% this year but up by about 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-proposes-whopping-1-trillion-pay-package-for-ceo-elon-musk/chwIJkaRdpr">Tesla Proposes Whopping $1 Trillion Pay Package For CEO Elon Musk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

Why Did BioNTech Stock Surge 10% Pre-Market Today?

DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.

Current Price	$35.31
Prev Close	$36.13
Open	$35.82
Dividend Yield	N/A
50-Day Moving Average	$37.36
Beta	N/A
Avg. Volume	56,469.12
PE Ratio	N/A

52-Week High	$39.06
52-Week Low	$26.18
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

APIE
Trust For Professional Managers - ActivePassive International Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Latest APIE News

APIETrust For Professional Managers - ActivePassive International Equity ETF